Insulin for All Act of 2023

The Insulin for All Act of 2023 sets a federal price cap of $20 per 1,000 units of insulin sold in the U.S., applying to all insulin products licensed under federal law (including vials, pens, and cartridges). This directly affects insulin manufacturers by restricting their pricing and benefits people with diabetes who rely on insulin for daily health management. The law establishes a specific, enforceable price limit for all covered insulin products, regardless of brand or delivery method. It creates a concrete policy change by replacing current market pricing with a fixed maximum cost.